TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05233124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid 100mg
Description: Acetylsalicylic acid 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 Mg Oral Tablet
Description: Clopidogrel 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 Mg Oral Tablet
Description: Clopidogrel 75mg
Study: NCT05432310

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
Description: Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan
Study: NCT04415554

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiography exam of the infant

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiography exam of the infant
Study: NCT05687370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified dynamic needle tip positioning under ultrasound-guidance
Description: The tip of needle is positioned under ultrasound-guidance using modified dynamic short-axis view.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-axis technique
Description: The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
Study: NCT06361433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUFF-01
Description: autologous MSC combined with scaffold
Study: NCT06558292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Group
Description: Students will experience the operating room environment with virtual reality glasses before clinical practice.
Study: NCT05267886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine administered according to its clinical dose stage for cardiogenic shock

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Milrinone administered according to its clinical dose stage for cardiogenic shock

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline running at a standardized rate
Study: NCT05046899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOpH+ Psoriasis Medical Bath
Description: 20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil Moisturizing Lotion
Description: Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
Study: NCT04804046

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with three Bifidobacterium spp. (3x10\^9 CFU) plus three dietary fibers (24 g fiber) daily for six months.
Study: NCT05243394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified virtual reality treadmill gait training with tDCS
Description: Progressive treadmill gait training in a gamified virtual reality environment with tDCS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified virtual reality treadmill gait training
Description: Progressive treadmill gait training in a gamified virtual reality environment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill gait training
Description: Progressive treadmill gait training
Study: NCT06179030

Intervention type: DIAGNOSTIC_TEST
Intervention: serum samples
Description: The serum samples were taken from the patients at the 3rd month (switch point)

Intervention type: DIAGNOSTIC_TEST
Intervention: serum samples
Description: The serum samples were taken from the patients at the 3rd month (switch point)

Intervention type: DRUG
Intervention: dexamethasone implant versus ranibizumab
Description: dexamethasone implant versus ranibizumab will be studied as a secondary outcome

Intervention type: DRUG
Intervention: dexamethasone implant versus ranibizumab
Description: dexamethasone implant versus ranibizumab will be studied as a secondary outcome
Study: NCT05154513

Intervention type: OTHER
Intervention: Cohort 1
Description: No intervention provided in this study
Study: NCT06092853

Intervention type: OTHER
Intervention: Gingival crevicular fluid (GCF) and serum samples
Description: Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses

Intervention type: OTHER
Intervention: Gingival crevicular fluid (GCF) and serum samples
Description: Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses

Intervention type: OTHER
Intervention: Gingival crevicular fluid (GCF) and serum samples
Description: Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses

Intervention type: OTHER
Intervention: Gingival crevicular fluid (GCF) and serum samples
Description: Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
Study: NCT04907591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth App and wearable device
Description: an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band worn on wrist for 12 months.
Study: NCT04883658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(2)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(2)
Description: QD, PO
Study: NCT04887532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR19042 capsule
Description: phase 1 :8mg; phase 2:12mg; phase 3:16mg
Study: NCT05691933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block group
Description: Patient will be subjected to bilateral external oblique intercostal plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Morphine infusion
Description: Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
Study: NCT05730842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-5506 Tablet
Description: Single Oral Dose - Tablet
Study: NCT04883658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study: NCT05233982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Product
Description: Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
Study: NCT05653297

Intervention type: DEVICE
Intervention: Vacuum-Assisted Closure
Description: NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
Study: NCT05730842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled EDG-5506 Suspension
Description: Single Oral Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled EDG-5506 Intravenous
Description: Single Intravenous Dose
Study: NCT05424601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rethink game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rethink game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsyPills
Description: PsyPills is a mobile app designed to provide personalized psychological pills
Study: NCT06427395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 1 mg
Description: Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
Study: NCT05042206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram-CKD
Description: Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
Study: NCT06305208

Intervention type: DEVICE
Intervention: Endoscopic gastric suturing
Description: Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.

Intervention type: DEVICE
Intervention: Endoscopic gastric plication
Description: Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.

Intervention type: DEVICE
Intervention: Revisional gastroplasty
Description: Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss

Intervention type: DEVICE
Intervention: Transoral outlet reduction endoscopy (TORe)
Description: Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
Study: NCT04804046

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Digestible Maltodextrin
Description: Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with Maltodextrin daily for six months.
Study: NCT06268990

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
Study: NCT05110807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3617
Description: TQB3617 is a BET inhibitor.
Study: NCT05545111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1117568
Description: Active treatment with orally administered NBI-1117568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1117568
Description: Active treatment with orally administered NBI-1117568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1117568
Description: Active treatment with orally administered NBI-1117568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1117568
Description: Active treatment with orally administered NBI-1117568

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching NBI-1117568
Study: NCT04918160

Intervention type: OTHER
Intervention: Exposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)
Description: The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).

Intervention type: OTHER
Intervention: Exposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)
Description: The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).
Study: NCT04744324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-supporting Care
Description: Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home health education
Description: Individualized home health education
Study: NCT04917718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion from IR Tacrolimus to XR Tacrolimus
Description: All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus
Study: NCT05015335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: ADA 40mg q2w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: MTX 10mg qw
Study: NCT04772391

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Sessions
Description: Participant will complete up to 8 exercise sessions
Study: NCT05333237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #1: ProvideXtra Drink
Description: Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
Study: NCT06268990

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
Study: NCT04968756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective retina therapy SPECTRALIS CENTAURUS device
Description: Microsecond laser microsurgery by using the SPECTRALIS CENTAURUS device
Study: NCT04882553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic echography
Description: Echography of the diaphragm at the zone of apposition. End-inspiratory and/or end-expiratory thickness of the diaphragm will be measured in M-mode.
Study: NCT06305208

Intervention type: DEVICE
Intervention: Duodenal mucosal resurfacing (DMR)
Description: Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.

Intervention type: DEVICE
Intervention: Intragastric balloon(s)
Description: The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.
Study: NCT05166668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg tablet
Description: letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg tablet
Description: letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
Study: NCT05420948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.
Study: NCT05333237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #2: Fresubin Energy Drink
Description: Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #2: Fresubin Energy Drink
Description: Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #2: Fresubin Energy Drink
Description: Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #3: Generic Glucose Solution
Description: Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
Study: NCT05420948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A chemotherapy drug used to treat cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A chemotherapy drug used to treat cancer.
Study: NCT05333237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #3: Generic Glucose Solution
Description: Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #3: Generic Glucose Solution
Description: Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
Study: NCT05425017

Intervention type: OTHER
Intervention: Range of motion with spinal adjustment
Description: With accelerometers affixed to spine recording vibrations, the participants complete range of motion. After completing, they receive a low back spinal adjustment and repeat range of motion

Intervention type: OTHER
Intervention: Range of motion with spinal adjustment
Description: With accelerometers affixed to spine recording vibrations, the participants complete range of motion. After completing, they receive a low back spinal adjustment and repeat range of motion
Study: NCT06252376

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head-up tilt table
Description: Different versions of cognitive assessments will be administered in the supine and upright positions while the participant is on the tilt table.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head-up tilt table
Description: Different versions of cognitive assessments will be administered in the supine and upright positions while the participant is on the tilt table.
Study: NCT06481670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: The \>50 g carbohydrate drink will be consumed up to 2 hours prior to surgery.
Study: NCT05626491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Description: Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Description: Patients receive sham treatment (no active stimulation) every other day via a headband.
Study: NCT05285891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Ocrelizumab
Description: Placebo infusions every 6 months from Month 30 through Month 48.
Study: NCT04770493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Participants will be randomized to lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks. A comparator group will receive placebo (sugar pills).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (sugar pill)
Study: NCT05027568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-289
Description: Daily oral twice daily dosing of IOA-289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel / gemcitabine
Description: Given in combination with IOA-289
Study: NCT06072196

Intervention type: DRUG
Intervention: Novel hormonal therapy
Description: As provided in real-world setting
Study: NCT05333237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #3: Generic Glucose Solution
Description: Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
Study: NCT06247735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-808 (Dose A)
Description: Administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: K-808 (Dose A)
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-808 (Dose B)
Description: Administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: K-808 (Dose B)
Description: Administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily